◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY
Franklin Genomic Advancements ETF (HELX) ETF Overview
Price history, fund statistics and profile — an exchange-traded fund.
Exchange-Traded Funds · Health · DATA UPDATED 2026-08-31
Franklin Genomic Advancements ETF (HELX) is an exchange-traded fund managed by Franklin Templeton Investments in the "Health" category. It manages roughly $29 million in assets.
Under normal market conditions, the fund invests at least 80% of its net assets in equity securities of companies that are relevant to its investment theme of genomic advancements. The fund invests predominantly in common stock.
Interactive chart & fund stats →
HELX Fund Statistics
| Expense ratio | 0.50% |
| Trailing yield | 0.37% |
| Assets under management | $29 million |
| Fund category | Health |
| Fund family | Franklin Templeton Investments |
| Inception | 2020-02-25 |
The live price chart, fund profile and news are in the interactive HELX viewer.
Other Companies in Health
About TickerBase · Data methodology & sources · Privacy · Terms
TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.